



DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

#DYK
Did you know?



Marketed drugs for DLBCL, including **Rituximab** and its biosimilars, as well as **Polatuzumab Vedotin** and **Tafasitamab**, are **widely available** across the United States, Europe, and Asia

In the Asia-Pacific region, **China** reported an estimated **higher incidence** of DLBCL cases

The **United States** had the **highest estimated** number of DLBCL cases in North America

In Europe, **Germany** reported an **estimated higher incidence** of DLBCL

In ROW, **Brazil** reported the **highest incidence** of DLBCL

2022: NEARLY
194k
DLBCL CASES



Phase III trials for **Mosunetuzumab** and **Selinexor** are progressing globally, **offering promising advancements** and potential new treatment options for DLBCL

DLBCL is the **most common and aggressive** subtype of non-Hodgkin lymphoma (NHL), accounting for **30-40%** of all NHL cases worldwide

DIFFUSE LARGE B-CELL LYMPHOMA CANCER TRIAL CONTRIBUTIONS



The Asia-Pacific region shows recruitment rates comparable to those of the United States

